On November 20, 2015 the U.S. Government Accountability Office (GAO) publicly released a report that found that expenditures for new drugs were concentrated among a small number of drugs and conditions, and most new Part B drugs were costly for beneficiaries. GAO identified expenditures in 2013 for 75 of the 83 new Part B drugs. Expenditures for these drugs were concentrated among 3 drugs which accounted for 53 percent of the $5.9 billion Medicare and its beneficiaries spent on new Part B drugs.
The full report can be found here.
The report highlights can be found here.
